ANX 005
Alternative Names: ANX-005Latest Information Update: 01 Jul 2024
At a glance
- Originator Annexon
- Class Antianaemics; Monoclonal antibodies
- Mechanism of Action Complement C1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Guillain-Barre syndrome
- Phase II Amyotrophic lateral sclerosis; Autoimmune haemolytic anaemia; Huntington's disease
- No development reported Autoimmune disorders; Neurodegenerative disorders
Most Recent Events
- 25 Jun 2024 Efficacy and adverse events data from a phase III trial in Guillain-Barre syndrome released by Annexon
- 10 Jun 2024 Efficacy and adverse events data from a phase III trial in Guillain-Barre syndrome released by Annexon
- 04 Jun 2024 Annexon Biosciences plans to submit BLA for Guillain-Barre syndrome in the first half of 2025